RxDoctor Payments Data

Sameer Sawalha, MD

Internal Medicine · Dearborn, MINPI 1730152216

Payments from drug & device makers

$199in general payments, 2019–2025

Across 12 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$53
  • GSK$39
  • Amgen$37
  • Lilly USA, LLC$24
  • Novartis$18
  • Sanofi Pasteur Inc.$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer4$53
GSK2$39
Amgen2$37
Lilly USA, LLC1$24
Novartis1$18
Sanofi Pasteur Inc.1$15
Novo Nordisk1$14

How this compares

$199 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$178,142
Medicare patients
196
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanumetSitagliptin Phos/Metformin Hcl244$154,418
TrulicityDulaglutide156$150,471
OzempicSemaglutide136$128,526
JardianceEmpagliflozin161$112,730
EliquisApixaban173$111,502
Fluticasone-SalmeterolFluticasone Propion/Salmeterol304$96,079
LinzessLinaclotide165$93,271
TradjentaLinagliptin155$84,041
JentaduetoLinagliptin/Metformin Hcl149$83,887
FarxigaDapagliflozin Propanediol141$81,561
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$76,915
JanuviaSitagliptin Phosphate77$52,957
XareltoRivaroxaban61$46,971
Albuterol Sulfate HfaAlbuterol Sulfate1,200$45,448
EntrestoSacubitril/Valsartan41$33,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$24$150,471156 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$39$134,402262 claims
Novo NordiskOzempic$14$128,526136 claims
PfizerEliquis$53$111,502173 claims
NovartisEntresto$18$33,87941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →